(Q44596250)

4 December 2017

Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma (English)

1 reference

4 December 2017

0 references

0 references

C Pothirat

3

0 references

author name string

W Boonsawat

1

1 reference

4 December 2017

S Charoenratanakul

2

1 reference

4 December 2017

K Sawanyawisuth

4

1 reference

4 December 2017

T Seearamroongruang

5

1 reference

4 December 2017

T Bengtsson

6

1 reference

4 December 2017

R Brander

7

1 reference

4 December 2017

O Selroos

8

1 reference

4 December 2017

1 September 2003

1 reference

4 December 2017

1 reference

4 December 2017

97

1 reference

4 December 2017

9

1 reference

4 December 2017

1067-1074

1 reference

Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency

4 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Formoterol fumarate, a new beta 2-adrenoceptor agonist. Acute studies of selectivity and duration of effect after inhaled and oral administration

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Relative systemic dose potency and tolerability of inhaled formoterol and salbutamol in healthy subjects and asthmatics

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Relative therapeutic index between inhaled formoterol and salbutamol in asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Measuring quality of life in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Onset and duration of action of single doses of formoterol inhaled via Turbuhaler

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0954-6111%2803%2900139-2

7 January 2021

10.1016/S0954-6111(03)00139-2

Identifiers

DOI

1 reference

4 December 2017

1 reference